Botfet / Company detail

SYRE

rejected

Spyre Therapeutics, Inc.

biotech

Moat scoreNot available: not scored quality failout of 100

Rejectionquality_fail

The numbers

Financial metrics

Quality gate and thesis context

Roic-29.1%

Gross Margin0.0%

Revenue Cagr-78.3%

Fcf Conversion109.0%

Fcf Yield-1.9%

Interest Coverage0.0x

Market Cap B$8.7B

PeNot available: not applicable loss making

Quality PassFail

Founder LedNo

Thesis AlignedYes

Moat QuantNot available: not scored quality fail

Why it may endure

Quant: · Curator:

Market Share StabilityNot available: not scored quality fail

Network EffectsNot available: not scored quality fail

Pricing PowerNot available: not scored quality fail

Regulatory MoatNot available: not scored quality fail

Switching CostsNot available: not scored quality fail

ConvictionNot available: not scored quality fail

LeadershipNot available: not scored quality fail

VisionNot available: not scored quality fail